Key Takeaways JNJ submitted an EMA filing for icotrokinra to treat plaque psoriasis in adults and pediatric patients.Four phase III ICONIC studies met primary and co-primary endpoints with positive results.Treatment showed significant skin clearance and favorable safety with once-daily oral dosing.Johnson & Johnson (JNJ) has submitted a regulatory filing to the European Medicines Agency (EMA) to seek approval for its investigational oral peptide, icotrokinra, to treat moderate-to-severe plaque psoriasis in ...